Exemplary Dual Regulatory Background Bridging Washington and Beijing
Dr. Li Zili's appointment as controller for medical products regulation marks a decisive recruitment milestone for Hong Kong's regulatory overhaul. The government confirmed on Monday that Dr. Li will lead the Centre for Medical Products Regulation, scheduled to launch later this year, with the strategic mission of driving proactive primary evaluations and ensuring expedited patient access to safe, high-efficacy pharmaceutical innovations.
Dr. Li boasts a unique professional pedigree, having earned his medical degree from Peking Union Medical College before completing residency training and acquiring a Master of Public Health from Johns Hopkins University. He completed two tenures at the US FDA, serving as medical team leader and subsequently as head of global affairs at the Office of Generic Drugs.














